ArticleCancer research and treatment2025
Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2022.
Article in Cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Comprehensive Computed Tomography Evaluation of Gastric Cancer: 2026 Consensus Recommendation From the Korean Society of Abdominal Radiology.Korean journal of radiology · 2026Guideline
- Korean Colorectal Cancer Screening Guidelines for Asymptomatic, Average-Risk Adults: The 2025 Revision.Cancer research and treatment · 2026Pooled it
- Effect Size of Factors Influencing Colorectal Cancer Survivors' Quality of Life: A Systematic Review and Meta-Analysis.Cancer medicine · 2026Pooled it
- Prevalence and determinants of polypharmacy among cancer patients: a systematic review and meta-analysis.Systematic reviews · 2026Pooled it
- Isolated para-aortic lymph node recurrence from colorectal cancer treated by radiotherapy: a systematic review and meta-analysis.Scientific reports · 2026Pooled it
- 2025 Korean Thyroid Association Clinical Management Guideline on Active Surveillance for Low-Risk Papillary Thyroid Carcinoma.Endocrinology and metabolism (Seoul, Korea) · 2025Guideline
- Covert Promotional Cancer-Related Content in Korean Search Engines: Computational Content Analysis of Naver and Google.Journal of medical Internet research · 2026Article
- Differential Cancer Risks and Noninvasive Predictors in MASLD, MetALD, and ALD: A Longitudinal Analysis.Gut and liver · 2026Article
- Reconsidering First-Line Therapy for Clarithromycin-ResistantGut and liver · 2026Article
- Statin Initiation and Mortality After Colorectal Cancer Treatment.JAMA network open · 2026Article
- Clinical utility of endorectal balloons in prostate cancer external beam radiotherapy: a systematic review and meta-analysis.Radiation oncology journal · 2026Article
- Cancer burden and control in China: landscape, trends and challenges.Nature reviews. Clinical oncology · 2026Review
- Development of a postoperative risk scoring tool for elderly patients with early gastric cancer: an exploratory prognostic score derivation study.Journal of gastrointestinal oncology · 2026Article
- Interim Positron Emission Tomography-Adapted Treatment Strategies for Classic Hodgkin Lymphoma: Insights From Korean Real-World Data.Journal of Korean medical science · 2026Article
- Depression and increased cancer risk: a 10-year population-based cohort study.Social psychiatry and psychiatric epidemiology · 2026Article
- A β‑1,3‑1,6‑glucan fromMolecular medicine reports · 2026Article
- Neoadjuvant Paclitaxel-Carboplatin Chemotherapy Followed by Cesarean Radical Hysterectomy in Pregnant Patients With Cervical Cancer: Obstetric, Neonatal, and Surgical Outcomes.The journal of obstetrics and gynaecology research · 2026Article
- Decline in Years of Life Lost Due to Diabetes in Korea, 2008-2019: A Cause-Specific Decomposition Analysis.Endocrinology and metabolism (Seoul, Korea) · 2026Article
- Shifting Cancer Landscapes in Korea: Divergent Incidence Trajectories, Sex-Specific Burdens, and Projected Case Counts for 24 Major Cancer Types from 1999 to 2023, with Forecasts to 2030.Current oncology (Toronto, Ont.) · 2026Article
- Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeThe current study provides national cancer statistics and their secular trends in Korea, including incidence, mortality, survival, and prevalence in 2022, with international comparisons. MATERIALS AND
methodsCancer incidence, survival, and prevalence rates were calculated using the Korea National Cancer Incidence Database (1999-2022), with survival follow-up until December 31, 2023. Mortality data obtained from Statistics Korea, while international comparisons were based on GLOBOCAN data.
resultsIn 2022, 282,047 newly diagnosed cancer cases (age-standardized rate [ASR], 287.0 per 100,000) and 83,378 deaths from cancer (ASR, 65.7 per 100,000) were reported. The proportion of localized-stage cancers increased from 45.6% in 2005 to 50.9% in 2022. Stomach, colorectal, and breast cancer showed increased localized-stage diagnoses by 18.1, 18.5, and 9.9 percentage points, respectively. Compared to 2001-2005, the 5-year relative survival (2018-2022) increased by 20.4 percentage points for stomach cancer, 7.6 for colorectal cancer, and 5.6 for breast cancer. Korea had the lowest cancer mortality among countries with similar incidence rates and the lowest mortality-to-incidence (M/I) ratios for these cancers. The 5-year relative survival (2018-2022) was 72.9%, contributing to over 2.59 million prevalent cases in 2022.
conclusionSince the launch of the National Cancer Screening Program in 2002, early detection has improved, increasing the diagnosis of localized-stage cancers and survival rates. Korea recorded the lowest M/I ratio among major comparison countries, demonstrating the effectiveness of its National Cancer Control Program.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.